Q2
ASMB — Q2 2026 Financial Report Analysis
Assembly Biosciences' Q2 loss narrowed to $3.9M ($0.20/share) mostly on a one-time $5.1M Gilead revenue catch-up, while a $115M May offering lifted cash to $320.4M and runway into late 2028 ahead of 6250 Phase 2 starts.